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(HCC) Assessment Randomized Protocol (SHARP) trial demon-
strated that sorafenib improves overall survival and is safe for
patients with advanced HCC. In this trial, 602 patients with
well-preserved liver function (>95% Child–Pugh A) were random-
ized to receive either sorafenib 400 mg or matching placebo
orally b.i.d. on a continuous basis. Because HCC is a heteroge-
neous disease, baseline patient characteristics may affect individ-
ual responses to treatment. In a comprehensive series of
exploratory subgroup analyses, data from the SHARP trial were
analyzed to discern if baseline patient characteristics inﬂuenced
the efﬁcacy and safety of sorafenib.Journal of Hepatology 20
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 On behalf of the SHARP Investigators Study Group.ogy, tumor burden, performance status, tumor stage, and prior
therapy. Overall survival (OS), time to progression (TTP), disease
control rate (DCR), and safety were assessed for subgroups within
each domain.
Results: Subgroup analyses showed that sorafenib consistently
improved median OS compared with placebo, as reﬂected by haz-
ard ratios (HRs) of 0.50–0.85, similar to the complete cohort
(HR = 0.69). Sorafenib also consistently improved median TTP
(HR, 0.40–0.64), except in HBV-positive patients (HR, 1.03), and
DCR. Results are limited by small patient numbers in some sub-
sets. The most common grade 3/4 adverse events included diar-
rhea, hand-foot skin reaction, and fatigue; the incidence of
which did not differ appreciably among subgroups.
Conclusions: These exploratory subgroup analyses showed that
sorafenib consistently improved median OS and DCR compared
with placebo in patients with advanced HCC, irrespective of dis-
ease etiology, baseline tumor burden, performance status, tumor
stage, and prior therapy.
 2012 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Hepatocellular carcinoma (HCC) is often diagnosed at an
advanced stage, when most potentially curative therapies, such
as resection, transplantation, and percutaneous ablation, are of
limited utility [1–3]. Only approximately 30–40% of patients are
diagnosed at an early stage and can beneﬁt from such curative12 vol. 57 j 821–829
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therapies [1,2], and up to 70% of patients who undergo these pro-
cedures will have recurrent disease within 5 years and reach a
more advanced tumor stage [4,5]. Patients diagnosed at an inter-
mediate stage can beneﬁt from transarterial chemoembolization
(TACE) but after an initial therapeutic beneﬁt, most patients pro-
gress to advanced stage.
Sorafenib is a multitargeted tyrosine kinase inhibitor that
blocks the activity of Raf serine/threonine kinase isoforms, as
well as the receptor tyrosine kinases vascular endothelial growth
factor receptors (VEGFR)-2 and -3, platelet-derived growth factor
receptor (PDGFR) b, c-KIT, FLT-3, and RET, to inhibit tumor angi-
ogenesis and tumor cell proliferation [6–8]. Results from the mul-
tinational, randomized, placebo-controlled, phase III Sorafenib
HCC Assessment Randomized Protocol (SHARP) trial demon-
strated that sorafenib signiﬁcantly improved overall survival
(OS) in patients with advanced HCC and well-preserved liver
function (>95% Child–Pugh A), and that drug-related adverse
events (AEs) were manageable [9]. Median OS in the sorafenib
and placebo groups was 10.7 and 7.9 months, respectively (haz-
ard ratio [HR] 0.69, 95% conﬁdence interval [CI] 0.55–0.87;
p <0.001), median time to progression (TTP) was 5.5 and
2.8 months, respectively (HR 0.58, 95% CI 0.45–0.74; p <0.001),
and disease control rate (DCR) was 43% and 32%, respectively
(p = 0.002) [9]. The positive impact of sorafenib in improving sur-
vival and delaying tumor progression was conﬁrmed in the phase
III Sorafenib Asia–Paciﬁc trial, performed in China, South Korea,
and Taiwan [10]. Together, these trials provided evidence for
the effectiveness of sorafenib across a range of disease etiologies,
leading to its approval as ﬁrst-line systemic therapy for patients
with advanced HCC [3,11–16].
Baseline characteristics may affect individual responses to
treatment. To discern whether baseline patient characteristics
inﬂuenced the efﬁcacy and safety of sorafenib in patients with
HCC, we performed a comprehensive series of exploratory sub-
group analyses to evaluate whether patient and/or tumor charac-
teristics at baseline affected response to sorafenib in the SHARP
trial. Five subgroup domains were selected for analysis: HCC eti-
ology (hepatitis C virus (HCV), hepatitis B virus (HBV) or alcohol-
related), tumor burden (deﬁned as macroscopic vascular invasion
(MVI) and/or extrahepatic spread (EHS)), Eastern Cooperative
Oncology Group performance status (ECOG PS), tumor stage
according to the Barcelona Clínic Liver Cancer (BCLC) system,
and treatment received prior to sorafenib. We did not include
gender, as this had already been reported in the original study
[9].Patients and methods
Study design
The SHARP study design has been described [9]. Brieﬂy, SHARP was a multina-
tional, randomized, double-blind, placebo-controlled, phase III trial evaluating
the clinical beneﬁts of sorafenib in patients with measurable, unresectable,
advanced HCC who had not received prior systemic therapy and with a Child–
Pugh A classiﬁcation of liver function, an ECOG PS of 0–2, and a life expectancy
of at least 12 weeks. Patients were randomized 1:1 to sorafenib 400 mg or match-
ing placebo twice daily. The primary end points included OS (measured from the
date of randomization to date of death from any cause) and patient-reported
quality of life [17], and safety. Tumor size was measured by computed tomogra-
phy or magnetic resonance imaging at screening, every 6 weeks during treatment,
and at the end of treatment. TTP was measured from the date of randomization to
the date of disease progression according to Response Evaluation Criteria in Solid
Tumors (RECIST). DCR was deﬁned as the percentage of patients who had a best822 Journal of Hepatology 201response of complete response (CR), partial response (PR), or stable disease (SD)
for P4 weeks, based on independent radiologic review. Safety was evaluated
according to the National Cancer Institute Common Terminology Criteria for
Adverse Events (NCI-CTCAE) version 3.0.
The 602 patients in the SHARP trial were stratiﬁed by tumor burden (pres-
ence or absence of MVI and/or EHS), ECOG PS (0 or 1–2), and geographic region
(North America; Central/South America; or Europe/Australia/New Zealand) and
randomized to receive sorafenib or placebo in a double blinded fashion [9]. For
the subset analyses, patients were subgrouped by tumor burden (MVI/EHS
absent; MVI/EHS present) and ECOG PS (0, 1–2); and post hoc by etiology (HCV,
HBV, alcohol); BCLC stage (B, C/D); and prior therapy (curative treatment, TACE).
Designation of alcohol as an etiologic factor was made by the investigator based
on history. Laboratory screening for HBV or HCV antigen was performed at least
7 days prior to initial treatment. Any previous local therapy must have been com-
pleted at least 4 weeks prior to the baseline scan and any treatment-naïve target
lesion was identiﬁed for proper assessment of tumor progression.
Statistical analysis
The population for efﬁcacy analysis in each subgroup was the intent-to-treat pop-
ulation (deﬁned as all randomized patients). OS and TTP were estimated by Kap-
lan–Meier analysis. Because the SHARP study was not powered for subgroup
analysis, the sorafenib and placebo subgroups were compared descriptively
rather than statistically. Furthermore, as in any post hoc subgroup analysis, statis-
tical strength decreases as sample size decreases, thereby obviating a formal
assessment of statistical signiﬁcance in cohorts with small sample sizes. We
report HR and 95% CI only, calculated from a Cox regression with only treatment
in the model.
The safety population included all patients who received at least one dose of
study drug. AEs were summarized descriptively. The sorafenib and placebo
groups were compared for the incidence of drug-related, treatment-emergent
AEs, and serious AEs (SAEs).Results
Baseline demographics, the major etiology of HCC, and disease
characteristics of patients in the SHARP subgroups are shown in
Table 1. Table 2 shows a summary of the efﬁcacy results (OS,
TTP, and DCR) of the subgroup analyses, as well as the results
in the overall population.
The mean daily doses in the sorafenib and placebo groups
were 710.5 ± 142.1 and 774.8 ± 65.4 mg, respectively, and the
median daily doses were 797.2 and 800.0 mg, respectively. Over-
all, 227 (75.7%) and 284 (93.8%) patients in the sorafenib and pla-
cebo groups, respectively, received average daily doses P80%,
and 204 (68.0%) and 269 (88.8%) patients, respectively, received
average daily doses P90%, of the planned daily dose.OS, TTP, and DCR by subgroups
Tumor etiology
Three subsets were included in the analysis of etiology (Fig. 1):
patients positive for anti-HCV antibody (n = 167), those positive
for HBV surface antigen (HBsAg; n = 60), and those classiﬁed as
presenting with alcohol-related HCC (n = 159). HCV-infected
patients treated with sorafenib had superior median OS (14.0 vs.
7.4 months), TTP (7.6 vs. 2.8 months), and DCR (44.2% vs. 29.6%)
than those who received placebo. Among HBV-positive patients,
those treated with sorafenib had a longer median OS (9.7 vs.
6.1 months), but a shorter median TTP (2.7 vs. 4.2 months) and a
similar DCR (34.4% vs. 32.1%) as those who received placebo. This
subset, however, was much smaller than the other subsets and
wasnotwell balanced, in that 18of 32 (56.3%) of those treatedwith
sorafenib had an ECOG PS of 1 or 2, compared with 11of 28
(39.3%) who received placebo (Table 1). Among patients with2 vol. 57 j 821–829
Table 1. Baseline demographic and disease characteristics of patients in SHARP trial exploratory subgroups (intent-to-treat populations).
Etiology of HCC MVI/EHS ECOG PS BCLC stage Prior therapy
HBV HCV Alcohol Both absent Either or both 
present
PS 0 PS 1/2 BC C B BCLC C† Curative TACE
n 
Sor
32
Pl
28
Sor
86
Pl
81
Sor
79
Pl
80
Sor
90
Pl
91
Sor
209
Pl
212
Sor
161
Pl
164
Sor
138
Pl
139
Sor
54
Pl
51
Sor
245
Pl
252
Sor
81
Pl
77
Sor
86
Pl
90
Median age (yr) 55.5 62.0 69.5 71.0 67.0 68.5 67.0 70.0 66.0 68.0 66.0 67.0 67.0 69.0 67.0 70.0 66.0 68.0 67.0 69.0 67.5 69.0
Male (%) 87.5 96.4 86.0 79.0 97.5 95.0 85.6 85.7 87.6 87.7 88.2 87.2 85.5 87.1 87.0 82.4 86.9 88.1 90.1 83.1 84.9 84.4
Region (%)
Europe*
North America
Central/ 
South America
96.9
0
 
3.1
96.4
0
 
3.6
90.7
9.3
 
0
88.9
9.9
 
1.2
93.7
5.1
 
1.3
95.0
3.8
 
1.3
93.3
4.4
 
2.2
86.8
9.9
 
3.3
85.6
11.0
 
3.3
86.8
9.4
 
3.8
91.3
8.1
 
0.6
90.2
9.1
 
0.6
84.1
10.1
 
5.8
82.7
10.1
 
7.2
94.4
3.7
 
1.9
90.2
7.8
 
2.0
86.5
10.2
 
3.3
86.1
9.9
 
4.0
86.4
8.6
 
4.9
84.4
13.0
 
2.6
90.7
7.0
 
2.3
76.7
16.7
 
6.7
ECOG PS (%)
0
1/2
43.7
56.3
60.7
39.3
51.2
48.8
53.1
46.9
60.8
39.2
52.5
47.5
60.0
40.0
56.0
44.0
51.2
48.8
53.3
46.7
100.0
0
100.0
0
0
100.0
0
100.0
100.0
0
100.0
0
43.7
56.3
44.8
55.2
55.6
44.4
75.3
24.7
62.8
37.2
60.0
40.0
Etiology‡
HBV
HCV
Alcohol
100.0
0
3.1
100.0
0
0
0
100.0
2.3
0
100.0
4.9
1.3
2.5
100.0
0
5.0
100.0
8.9
35.6
26.7
8.8
28.6
33.0
11.5
25.8
26.3
9.4
25.9
23.6
8.7
27.3
29.8
10.4
26.2
25.6
13.0
30.4
22.5
7.9
27.7
27.3
9.3
27.8
33.3
7.8
29.4
35.3
11.0
29.0
24.9
9.5
26.2
24.6
9.9
30.9
21.0
10.4
33.8
16.9
11.6
29.1
22.1
13.3
26.7
23.3
Child-Pugh class 
(%)
A
B/C
96.9
3.1
100.0
0
95.3
4.7
98.8
1.2
97.5
2.5
98.8
1.3
96.7
3.3
96.7
3.3
94.3
5.7
98.6
1.4
98.1
1.9
98.2
1.8
91.3
8.7
97.8
2.2
98.1
1.9
96.1
3.9
94.3
5.7
98.4
1.6
93.8
6.2
100.0
0
97.7
2.3
97.8
2.2
BCLC Stage (%)
B
C
15.6
84.4
14.3
85.7
17.4
82.6
18.5
81.5
22.8
77.2
22.5
77.5
60.0
40.0
56.0
44.4
0
100.0
0
100.0
33.5
66.5
31.1
68.9
0
100.0
0
100.0
100.0
0
100.0
0
0
100.0
0
100.0
23.5
76.5
22.1
77.9
29.1
70.9
18.9
81.1
MVI/EHS (%)
Both absent
Either or both 
present
25.0
75.0
28.6
71.4
37.2
62.8
32.1
67.9
30.4
69.6
37.5
62.5
100.0
0
100.0
0
0
100.0
0
100.0
33.5
66.5
31.1
68.9
26.1
73.9
28.8
71.2
100.0
0
100.0
0
14.7
85.3
15.9
84.1
38.3
61.7
32.5
67.5
41.9
58.1
33.3
66.7
⁄Includes Australia and New Zealand.
One patient had BCLC stage D disease.
The sum in each column exceeded 100%, since some patients were infected with HBV + HCV and others were infected with either virus + alcohol.
HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HCV, hepatitis C virus; Sor, sorafenib; Pl, placebo; ECOG PS, Eastern Cooperative Oncology Group pe rmance status; BCLC, Barcelona Clinic Liver Cancer; MVI,
macroscopic vascular invasion; EHS, extrahepatic spread.
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Table 2. Overall survival (OS), time to progression (TTP), and disease control rate (DCR) in subgroups and in the SHARP overall population.
Subgroup 
domain
Group evaluated Number of 
patients
OS (mo) TTP (mo) DCR (%)
Sor Pl Sor Pl HR (95% CI) Sor Pl HR (95% CI) Sor Pl
- SHARP overall populationa 299 303 10.7 7.9 0.69 (0.55-0.87) 5.5 2.8 0.58 (0.45-0.74) 43.5 31.7
Subgroup
Etiology of HCC Positive for anti-HCV 
antibody
86 81 14.0 7.4 0.50 (0.32-0.77) 7.6 2.8 0.43 (0.25-0.73) 44.2 29.6
Positive for HBsAg 
antigen
32 28 9.7 6.1 0.76 (0.38-1.50) 2.7 4.2 1.03 (0.52-2.04) 34.4 32.1
Alcohol 79 80 10.3 8.0 0.76 (0.50-1.16) 5.5 3.9 0.64 (0.40-1.03) 54.4 38.8
Tumor burden MVI/EHS both absent 90 91 14.5 10.2 0.52 (0.32-0.85) 9.6 4.3 0.40 (0.23-0.70) 48.9 40.7
MVI/EHS both present 209 212 8.9 6.7 0.77 (0.60-0.99) 4.1 2.7 0.64 (0.48-0.84) 41.2 27.8
MVI absent 190 179 14.1 10.2 0.74 (0.54-1.00) 7.3 3.9 0.57 (0.42-0.80) 45.8 35.2
MVI present 108 123 8.1 4.9 0.68 (0.49-0.93) 4.1 2.7 0.57 (0.39-0.84) 38.9 26.8
EHS absent 140 153 14.1 7.9 0.55 (0.39-0.77) 5.8 4.0 0.54 (0.37-0.79) 42.9 35.3
EHS present 159 150 8.9 8.3 0.85 (0.64-1.15) 5.3 2.7 0.58 (0.42-0.81) 44.0 28.0
Performance 
status
ECOG PS 0 161 164 13.3 8.8 0.68 (0.50-0.95) 5.5 2.9 0.55 (0.40-0.77) 46.6 36.0
ECOG PS 1-2 138 139 8.9 5.6 0.71 (0.52-0.96) 5.3 2.8 0.61 (0.42-0.88) 39.9 26.6
Tumor stage BCLC B 54 51 14.5 11.4 0.72 (0.38-1.38) 6.9 4.4 0.47 (0.23-0.96) 50.0 43.1
BCLC C* 245 252 9.7 7.0 0.70 (0.56-0.89) 4.9 2.8 0.59 (0.45-0.77) 42.0 29.4
Prior therapy Prior curative treatment† 81 77 11.9 8.8 0.79 (0.51-1.22) 5.5 2.8 0.62 (0.39-0.98) 49.4 32.5
Prior TACE 86 90 11.9 9.9 0.75 (0.49-1.14) 5.8 4.0 0.57 (0.36-0.91) 44.2 34.4
⁄Including one sorafenib-treated patient with tumor stage BCLC D.
Resection/local ablation, percutaneous ethanol injection, or radiofrequency ablation.
aLlovet et al., 2008 [9].
HCV, hepatitis C virus; HBV, hepatitis B virus; MVI, macrovascular invasion; EHS, extrahepatic spread; ECOG PS, Eastern Cooperative Oncology Conference performance
status; BCLC, Barcelona Clínic Liver Cancer; TACE, transarterial chemoembolization.
Research Articlealcohol-related HCC, sorafenib was associated with a longer med-
ian OS (10.3 vs. 8.0 months) and TTP (5.5 vs. 3.9 months) and a
higher DCR (54.4% vs. 38.8%) than placebo.
Tumor burden
Two subsets were included in the main analysis of tumor burden:
patients without both MVI and EHS (MVI/EHS absent; n = 181)
and those with MVI and/or EHS (MVI/EHS present; n = 421). We
also separately analyzed patients with and without MVI, and
those with and without EHS.
In each subset, sorafenib enhanced OS, TTP, and DCR com-
pared with placebo. For example, patients with MVI/EHS absent
who were treated with sorafenib (n = 90) had a longer median
OS (14.5 vs. 10.2 months) and TTP (9.6 vs. 4.3 months) and a
higher DCR (48.9% vs. 40.7%) than those who received placebo
(n = 91). In the MVI/EHS–present subgroup, sorafenib (n = 209)
was associated with a longer median OS (8.9 vs. 6.7 months)
and TTP (4.1 vs. 2.7 months) and a higher DCR (41.2% vs. 27.8%)
than placebo (n = 212). Similarly, patients without MVI treated
with sorafenib (n = 190) had a longer median OS (14.1 vs.
10.2 months) and TTP (7.3 vs. 3.9 months) and a higher DCR
(45.8% vs. 35.2%) than those who received placebo (n = 179);
and patients with MVI who were treated with sorafenib
(n = 108) had a longer median OS (8.1 vs. 4.9 months) and TTP
(4.1 vs. 2.7 months), and a higher DCR (38.9% vs. 26.8%) than
those who received placebo (n = 123). Among patients without
EHS, sorafenib (n = 140) was associated with a longer median824 Journal of Hepatology 201OS (14.1 vs. 7.9 months) and TTP (5.8 vs. 4.0 months) and a higher
DCR (42.9% vs. 35.3%) than patients who received placebo
(n = 153), and patients with EHS who were treated with sorafenib
(n = 159) had a slightly longer median OS (8.9 vs. 8.3 months), a
longer median TTP (5.3 vs. 2.7 months), and a higher DCR
(44.0% vs. 28.0%) than those who received placebo (n = 150).
ECOG PS
Two subsets were included in the analysis of ECOG PS: patients
with ECOG PS 0 (n = 325) and those with ECOG PS 1–2
(n = 277). Sorafenib treatment of patients with ECOG PS 0
(n = 161) resulted in a longer median OS (13.3 vs. 8.8 months)
and TTP (5.5 vs. 2.9 months) and a higher DCR (46.6% vs. 36.0%)
than placebo (n = 164). Similarly, sorafenib treatment of patients
with ECOG PS 1–2 (n = 138) resulted in a longer median OS (8.9
vs. 5.6 months) and TTP (5.3 vs. 2.8 months) and a higher DCR
(39.9% vs. 26.6%) than placebo (n = 139).
BCLC stage
Two subsets were included in the analysis of BCLC stage (Fig. 2):
patients with BCLC B not suitable for or refractory to locoregional
therapies (intermediate-stage; n = 105) and BCLC C (advanced-
stage; n = 497). BCLC B patients treated with sorafenib (n = 54)
had a longer median OS (14.5 vs. 11.4 months) and TTP (6.9 vs.
4.4 months) and a higher DCR (50.0% vs. 43.1%) than those who
received placebo (n = 51). Similarly, sorafenib treatment of BCLC
C patients (n = 245) resulted in a longer median OS (9.7 vs.2 vol. 57 j 821–829
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Fig. 1. Relationship between etiology of HCC and survival outcomes in
patients enrolled in the SHARP trial. Overall survival (OS) in patients with HCC
due to (A) hepatitis C virus (HCV) infection, (C) hepatitis B virus (HBV) infection,
and (E) chronic alcohol consumption. Time to progression (TTP) in patients with
HCC due to (B) HCV infection, (D) HBV infection, and (F) chronic alcohol
consumption.
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Fig. 2. Relationship between Barcelona Clínic Liver Cancer (BCLC) stage and
survival outcomes in patients enrolled in the SHARP trial. Overall survival (OS)
in patients with (A) BCLC B and (C) BCLC C stage. Time to progression (TTP) in
patients with (B) BCLC B and (D) BCLC C stage.
JOURNAL OF HEPATOLOGY7.0 months) and TTP (4.9 vs. 2.8 months) and a higher DCR (42.0%
vs. 29.4%) than placebo (n = 252). We also identiﬁed 220 patients
staged BCLC C because of MVI and/or EHS spread, but with an
ECOG PS of 0; of these, the 107 who received sorafenib had a
longer median OS (10.7 vs. 8.3 months) and TTP (4.9 vs.
2.8 months) than the 113 who received placebo (data not shown).
Previous treatment
The SHARP trial permitted the enrollment of patients previously
treated for HCC, with 158 (26.2%) receiving prior curative treat-
ments (e.g. partial hepatectomy, segmentectomy, wedge resec-
tion, radiofrequency ablation, or percutaneous ethanol
injection) and 176 (29.2%) who had undergone TACE (Fig. 3).
Sorafenib treatment of patients with prior curative treatment
(n = 81) resulted in a longer median OS (11.9 vs. 8.8 months) and
TTP (5.5 vs. 2.8 months) and a higher DCR (49.4% vs. 32.5%) than
placebo (n = 77). Similarly, sorafenib treatment of patients with
prior TACE (n = 86) resulted in a longer median OS (11.9 vs.
9.9 months) and TTP (5.8 vs. 4.0 months) and a higher DCR
(44.2% vs. 34.4%) than placebo (n = 90).Journal of Hepatology 201Safety
The incidence of adverse events (AEs) was similar across all
subgroups. The most frequently reported drug-related treat-
ment-emergent AEs in patients receiving sorafenib were diar-
rhea, fatigue, anorexia, and hand-foot skin reaction (HFSR). The
incidence of drug related AEs of any severity in the sorafenib
and placebo subgroups were 71.9–84.9% and 43.2–60.7%, respec-
tively, and the incidences of drug related SAEs were 9.4–14.6%
and 5.0–25%, respectively.
Composite results of the exploratory subgroup analyses and
the subgroup safety analysis are depicted schematically in Fig. 4.Discussion
In a series of exploratory subgroup analyses, we evaluated the
relative effects of baseline patient characteristics on the efﬁcacy
and safety of sorafenib in patients with advanced HCC who were
enrolled in the SHARP trial. In general, sorafenib consistently
improved OS, TTP, and DCR compared with placebo, irrespective
of baseline health status, disease etiology, tumor burden, tumor
stage, or prior therapy received.
Among the most frequent etiologic factors in patients with
HCC are chronic HBV infection, chronic HCV infection, and alco-
hol [3,18–21]. Although the mechanisms by which chronic viral
infection induces HCC may differ by speciﬁc virus and genotype,
HCC typically emerges after cirrhosis has become completely
established [21]. Similarly, chronic alcohol use induces oxidative
damage and inﬂammation in the liver, with subsequent repair
mechanisms causing cirrhosis and genetic aberrations [22]. It is
presently unclear, however, whether these etiologically different2 vol. 57 j 821–829 825
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Fig. 3. Relationship between prior treatment and survival outcomes in
patients enrolled in the SHARP trial. Overall survival (OS) in patients with (A)
prior curative treatment (resection/local ablation, percutaneous ethanol injection,
or radiofrequency ablation) and (C) prior transarterial chemoembolization
(TACE). Time to progression (TTP) in patients with (B) prior curative treatment
and (D) prior TACE.
Research Articleoncogenic mechanisms result in tumors that have different
genetic, as opposed to etiologic, characteristics and therefore0
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rate, and (D) frequency of grade 3/4 adverse events among subgroups of patients with
826 Journal of Hepatology 201may respond differently to treatment with sorafenib. In addition,
the incidence of these etiologies varies among different patient
populations [23,24]. HCC is most frequently associated with
chronic HBV infection in Africa and many Asian countries but
with chronic HCV infection and chronic alcohol use in Western
countries and Japan. Because the SHARP trial was performed in
Western populations, HCC in most of the enrolled patients was
associated with either HCV infection or chronic alcohol use [9].
Sorafenib improved OS, TTP, and DCR in patients with HCC due
to either etiology.
The SHARP trial was not randomized relative to etiology (i.e.
HBV vs. HCV vs. alcohol). Thus, the resulting subgroups were at
risk of imbalance. This clearly occurred among patients with
HBV-associated HCC, with the number of these patients being rel-
atively small, likely because the SHARP trial included centers in
Europe, North and South America and Australasia, areas in which
HBV is non-endemic, but did not include centers in Asia, where
HBV is endemic. Moreover, examination of the subset of patients
with HBV-associated HCC showed that 56.3% of those treated
with sorafenib, compared with 39.3% of those who received pla-
cebo, had an ECOG PS >0, indicating that the sorafenib group was
at a more advanced clinical stage [25,26]. This imbalance may
have confounded the results of our sub-analysis of patients with
HBV-associated HCC, in that OS was greater, while TTP was lower,
in sorafenib-treated patients. In the phase III Sorafenib Asia Paci-
ﬁc trial, which included centers in China, South Korea, and Tai-
wan, areas in which HBV infection is endemic, 165 of the 226
enrolled patients were infected with HBV; analysis showed that
sorafenib enhanced both OS (5.9 vs. 4.1 months; HR 0.74, 95%
CI 0.51–1.06) and TTP (2.8 vs. 1.4 months, HR 0.57, 95% CI
0.29–1.13), relative to placebo, in patients with HBV-associated
HCC [10,27], further suggesting that the results observed in
SHARP patients with HBV-associated HCC were due to patient
imbalance and not to these patients responding differently to
sorafenib. Moreover, a recent phase III trial reported that the: Overall SHARP population
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median OS in 288 patients with HBV-associated HCC treated with
sorafenib was 7.9 months [28].
Another possibility suggested by our sub-analysis was that
patients with HCV-related HCC derive more clinical beneﬁt from
sorafenib treatment than do patients with HBV-related HCC. In
addition, in vitro results in the human HuH7.5 liver cancer cell
line have suggested that sorafenib inhibits HCV replication [29].
Recent results have shown, however, that sorafenib had little or
no effect on HCV viral load in 18 patients with HCV-associated
HCC [30]. Thus, the combined results of these trials suggest that
sorafenib is effective for the treatment of advanced HCC irrespec-
tive of viral etiology.
Tumor burden has been deﬁned as MVI and EHS, both of
which have been shown to be independent factors affecting the
mortality of patients with HCC [25], and both of which are there-
fore included in many staging systems [31–41]. The occurrence of
MVI and/or EHS limits treatment options, in that curative treat-
ments (such as partial hepatectomy, radiofrequency ablation,
and percutaneous ethanol injection) and TACE are generally not
recommended. We found that, among patients in the SHARP trial,
sorafenib extended both OS and TTP in patients with and without
MVI and/or EHS, compared with placebo. Moreover, sorafenib
had the same safety proﬁle, irrespective of the presence of MVI
and/or EHS.
ECOG PS assesses the effect of a tumor on a patient’s daily liv-
ing ability [42], making it an important measure of patient health
and a strong indicator of prognosis [25,33,36]. ECOG PS is consid-
ered during treatment assignment and is included in staging sys-
tems, although patients with ECOG PS >2 are usually not treated
because of the high probability of poor short-term survival. When
we evaluated the OS, TTP, and DCR in patients with ECOG PS 0
and those with ECOG PS 1–2, we found that sorafenib was equally
effective, relative to placebo, and was well tolerated, in both
subsets.
The BCLC staging system, a widely used algorithm for the clas-
siﬁcation of HCC and the assignment of treatment that incorpo-
rates several prognostic factors, including tumor morphology,
liver function, and general patient performance status [32], has
been validated externally [40], and its components shown in a
meta-analysis to be an independent predictor of 1- and 2-year
survival rates [41]. BCLC B tumors are asymptomatic and without
MVI or EHS, whereas BCLC C tumors have already affected patient
performance status and/or are associated with MVI and/or EHS;
in the latter, a safe and effective treatment option was lacking
until the availability of sorafenib. Our subanalyses showed that
sorafenib was more effective than placebo in patients with BCLC
stages B and C tumors; however, the wide conﬁdence interval for
OS in the BCLC B subgroup did not allow a robust conclusion in
these patients.
Curative treatments available for patients with early-stage
HCC include organ transplantation and tumor removal by resec-
tion or percutaneous ablation [3]. TACE, which blocks the artery
feeding the tumor and injects a concentrated dose of chemother-
apeutic agent at the tumor site, is recommended for, and pro-
longs survival in, patients with intermediate-stage HCC who are
not candidates for curative treatments. Our analysis of patients
who had received prior curative therapies or TACE showed that
sorafenib improved TTP and demonstrated a trend toward
improved OS, irrespective of prior therapy.
Sorafenib has a favorable safety proﬁle, with a low incidence
of serious or life-threatening AEs in patients with HCC [9,10].Journal of Hepatology 201We found that the incidence of sorafenib-associated AEs was
not affected by any of our subgroupings, suggesting that sorafe-
nib is safe for use in a wide range of patients with HCC. The most
common AEs were diarrhea, HFSR, fatigue, and rash/desquama-
tion, all of which were considered medically manageable. Inter-
estingly, we observed no differences in HFSR related to etiology
(HBV vs. HCV).
Assessment of patient health and tumor stage inﬂuences the
selection of treatment at all stages of HCC. Individualized treat-
ment strategies are based on baseline characteristics. The param-
eters evaluated in this study are those usually evaluated during
this clinical decision-making process, with treatment designed
to optimize survival while maintaining quality of life. This is of
key importance in patients with HCC, as clinical status is affected
both by the tumor itself and by the impairment resulting from
the underlying liver disease. The results shown here conﬁrm that
the BCLC stratiﬁcation into intermediate and advanced stage is
valid, as those patients without MVI or EHS and ECOG PS 0 had
a 9–10 month OS with placebo; whereas those with an adverse
predictor (e.g. MVI, EHS, or ECOG PS 1 or 2) had an OS of 5–
6 months with placebo.
This study had several limitations. The SHARP study was not
originally empowered to assess outcomes in patient subgroups.
Therefore, we compared the sorafenib and placebo subgroups
descriptively rather than statistically. In addition, the numbers
of patients in some groups was small. Due to these limitations,
formal statistical testing was not performed; instead, we reported
HRs and 95% CIs, as calculated from a Cox regression analysis
with only treatment in the model.
The results of our SHARP trial subgroup analyses suggest that
the efﬁcacy and safety of sorafenib, relative to placebo, in
patients with advanced HCC and well-preserved liver function
do not appear to be affected by baseline health status, disease eti-
ology, tumor burden, tumor stage, or prior therapy.Financial support
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